

geron

J. Michael Schiff, Ph.D.
GERON CORPORATION
230 Constitution Drive
Menlo Park, CA 94025
Phone: (650) 473-7715
Fax: (650) 473-8654

Facsimile Transmittal Sheet

Date: October 23, 2003
To: Thai-An N. Ton. Ph.D., Art Unit 1632
U.S. PATENT AND TRADEMARK OFFICE
Fax #: (703) 872-9306
Phone #: (703) 305-1019
From: J. Michael Schiff, Ph.D.

RECEIVED
CENTRAL FAX CENTER

OCT 23 2003

OFFICIAL

Page 1 of 11 (including cover and ending sheet)

Re: U.S. Patent Application Serial No. 10/039,956
Gern Docket No. 091/009C

OFFICIAL FILING
Transmittal, Response to Restriction Requirement
and Preliminary Amendment for
USSN 10/039,956
Please enter this paper into the Patent File.

PTO/SB/21 (08-03)



Approved for use through 07/31/2008. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

| | | |
|--|----------|---|
| TRANSMITTAL FORM <i>(to be used for all correspondence after initial filing)</i> | | Application Number 10/039,956 |
| | | Filing Date October 23, 2001 |
| | | First Named Inventor Melissa K. Carpenter, et al. |
| | | Art Unit 1632 |
| | | Examiner Name Thai-An N. Ton |
| Total Number of Pages in This Submission | 5 | Attorney Docket Number 091/009C |

| ENCLOSURES <i>(Check all that apply)</i> | | |
|--|--|---|
| <input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/ Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53 | <input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation <input type="checkbox"/> Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____ | <input type="checkbox"/> After Allowance communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): |
| Remarks 1. Response to Restriction Requirement and Preliminary Amendment (8 pages) | | |

| SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT | |
|---|---|
| Firm or Individual name | J. Michael Schiff, Registration No. 40,253 |
| Signature |  |
| Date | October 23, 2003 |


| CERTIFICATE OF TRANSMISSION/MAILING | | |
|---|---|------|
| I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below. | | |
| Typed or printed name |  | |
| Signature |  | Date |
| | October 23, 2003 | |

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

CERTIFICATE OF FACSIMILE TRANSMISSION

I hereby certify that this correspondence is being transmitted to the U.S. Patent & Trademark Office
in accordance with 37 CFR § 1.8(d) on the date indicated.



Name



Date

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Inventors: Melissa Carpenter et al.

Art Unit: 1632

Filing Date: October 23, 2001

Examiner: Tháí-An N. Ton, Ph.D.

Serial No: 10/039,956

Docket: 091/009c

Title: TECHNIQUES FOR GROWTH AND
DIFFERENTIATION OF HUMAN
PLURIPOTENT STEM CELLSRECEIVED
CENTRAL FAX CENTER

OCT 23 2003

RESPONSE TO RESTRICTION REQUIREMENT
AND PRELIMINARY AMENDMENTCommissioner for Patents
Alexandria VA 22313

Dear Sir,

This paper is responsive to the Restriction Requirement mailed on September 23, 2003, for which a shortened statutory period for reply is set to expire on October 23, 2003. Accordingly, this paper is timely filed.

Please enter the following amendments and remarks.

PATENT
10/039,956
Docket 091/009c

CLAIM AMENDMENTS

1. *(Original)* A composition comprising proliferating primate pluripotent stem (pPS) cells, which is essentially free of feeder cells.

2 to 10. CANCELLED

11. *(Original)* A method for producing differentiated cells from a donor culture of undifferentiated primate pluripotent stem (pPS) cells, comprising:

- a) preparing a suspension of cells from the undifferentiated donor culture;
- b) replating and culturing the suspended cells on a solid surface so that they differentiate without forming embryoid bodies; and
- c) harvesting differentiated cells from the solid surface.

12. *(Original)* A method for producing differentiated cells from a donor culture of primate pluripotent stem (pPS) cells, comprising:

- a) providing a culture of primate pluripotent stem (pPS) cells that is essentially free of feeder cells;
- b) changing the medium in which the cells are cultured; and
- c) harvesting differentiated cells after culturing for a time in the changed medium.

13. *(Original)* The method of claim 11, wherein the donor culture of pPS cells is a culture essentially free of feeder cells, according to any of claims claim 1.

14. *(Original)* The method of claim 11, having at least one of the following features:

- i) the solid surface bears a poly-cation (such as poly-lysine or poly-ornithine);
- ii) differentiation is promoted by withdrawing serum, serum replacement, or a factor that inhibits differentiation from medium in which the cells are cultured after replating; or
- iii) differentiation is promoted by adding a factor (such as Brain Derived Neurotrophic Factor, BDNF; or Neurotrophin-3, NT-3) that promotes differentiation in medium in which the cells are cultured after replating.

15. *(Original)* A differentiated cell population produced by the method of claim 10 claim 35.

PATENT
10/039,956
Docket 091/009c

16. *(Original)* A method of screening a compound for cellular toxicity or modulation, comprising contacting a differentiated cell according to claim 15 with the compound, determining any phenotypic or metabolic changes in the cell that result from contact with the compound, and correlating the change with cellular toxicity or modulation.
17. *(Original)* A method for producing a polynucleotide comprising a nucleotide sequence contained in an mRNA that is expressed at a different level in committed or differentiated cells compared with undifferentiated primate pluripotent stem (pPS) cells, the method comprising:
 - a) determining the level of expression of a plurality of mRNAs in committed or differentiated cells, in comparison to the level of expression of the same mRNAs in undifferentiated pPS cells;
 - b) identifying an mRNA expressed at a different level in the committed or differentiated cells, relative to the undifferentiated pPS cells; and
 - c) preparing a polynucleotide comprising a nucleotide sequence of at least 30 consecutive nucleotides contained in the identified mRNA.

18 to 29. CANCELLED

30. *(Previously Presented)* A method for producing a protein containing a sequence of a polypeptide expressed in undifferentiated or differentiated pPS cells, comprising determining amino acid sequence from a protein encoding region of an mRNA or cDNA from an expression library, and manufacturing a protein containing the determined sequence;
wherein the expression library was obtained by providing a culture of undifferentiated pPS cells essentially free of feeder cells, optionally permitting the pPS cells to differentiate, and isolating mRNA from the undifferentiated or differentiated cells.
31. *(Previously Presented)* A method for producing an antibody specific for a polypeptide expressed in undifferentiated or differentiated pPS cells, comprising determining amino acid sequence from a protein encoding region of an mRNA or cDNA from an expression library, and immunizing an animal or contacting an immunocompetent cell or particle with a protein containing the determined sequence;
wherein the expression library was obtained by providing a culture of undifferentiated pPS cells essentially free of feeder cells, optionally permitting the pPS cells to differentiate, and isolating mRNA from the undifferentiated or differentiated cells.
32. *(Original)* The composition of claim 1, wherein the pPS cells are human embryonic stem (hES) cells.

33 to 34. CANCELLED

PATENT
10/039,956
Docket 091/009c

35. *(Original)* A method for producing a population of differentiated cells, comprising:
 - a) obtaining a line of embryonic stem cells that have been established in a culture environment that is essentially free of feeder cells; and
 - b) causing cells in the culture to differentiate into the population of differentiated cells.
36. **CANCELLED**
37. *(New)* A method of screening a substance for its effect on cultured cells, comprising:
 - a) obtaining a culture of undifferentiated pPS cells proliferating in a growth environment that is essentially free of feeder cells;
 - b) optionally causing or permitting the pPS cells to differentiate; then
 - c) combining the cells with the substance; and
 - d) determining any effect of the substance on the cells.
38. *(New)* The method of claim 37, wherein the undifferentiated pPS cells are cultured on extracellular matrix components (such as Matrigel®, laminin, or collagen) in the absence of feeder cells.
39. *(New)* The method of claim 37, wherein the cells are undifferentiated when contacted with the substance.
40. *(New)* The method of claim 37, wherein the cells have been caused or permitted to differentiate before being contacted with the substance.
41. *(New)* The method of claim 40, wherein the cells have been caused to differentiate by a process comprising replating them onto a surface that promotes differentiation.
42. *(New)* The method of claim 40, wherein the cells have been caused to differentiate by adding component(s) to the medium that promote differentiation towards a particular cell lineage.
43. *(New)* The method of claim 40, comprising causing the cells to differentiate into cells having characteristics of neuronal cells, glial cells, or neural precursors.
44. *(New)* The method of claim 40, comprising causing the cells to differentiate into cells having characteristics of hepatocytes.
45. *(New)* The method of claim 37, wherein the pPS cells are human embryonic stem (hES) cells.

PATENT
10/039,956
Docket 091/009c

46. (New) The method of claim 37, comprising determining the effect of the substance on growth of the cells.
47. (New) The method of claim 37, comprising determining whether the compound affects differentiation of the cells.
48. (New) The method of claim 37, comprising determining whether the compound affects expression of a marker or receptor by the cells.
49. (New) The method of claim 37, comprising determining whether the compound affects release of a marker or enzyme from the cells
50. (New) The method of claim 37, comprising determining whether the compound affects DNA synthesis or repair in the cells.
51. (New) The method of claim 37, comprising analyzing the cells by metaphase spread.
52. (New) The method of claim 37, comprising determining whether the compound is toxic to the cells.

PATENT
10/039,956
Docket 091/009c

AMENDMENT TO THE TITLE

Please change the TITLE of the application as follows:

**TECHNIQUES FOR GROWTH AND DIFFERENTIATION
OF HUMAN PLURIPOTENT STEM CELLS**

**USE OF HUMAN EMBRYONIC STEM CELLS
FOR DRUG SCREENING AND TOXICITY TESTING**

PATENT
10/039,956
Docket 091/009c

REMARKS

Claims 1-22 and 30-36 as previously presented are subject to a Restriction Requirement under 35 USC § 121 between claims in twelve groups.

As a result of entering this amendment, claims 1, 11-17, 30-32, 35, and 37-52 are now pending. Entry of the claim amendments does not introduce new matter into the disclosure. Support for the new claims may be found at various places in the specification, such as the following:

- Claims 37, 39, and 46-52 are supported by the section from page 34, line 40 to page 35, line 21 of the application as filed.
- Claim 38 is supported by claim 3 as originally filed.
- Claim 45 is supported by claim 32 as originally filed.
- Claims 39-44 are supported by the section from page 22, line 22 to page 24, line 36.

The amendments are made to obtain coverage for certain aspects of the invention that are of current commercial interest. Subject matter encompassed by the cancelled claims are being pursued in other applications (e.g., USSN 09/530,346; 09/688,031; 09/849,022; 09/859,291; 09/900,752; 09/994,440; 10/013,205; 10/087,473; 10/235,094; 10/330,873). Applicant reserves the right to introduce claims to subject matter previously claimed or described in the disclosure in this or any other application.

The title is amended to reflect the subject matter elected for examination. Applicant requests that the Examiner amend the Patent Office file accordingly.

Election of Group for Examination

Applicant hereby elects new method claim 37 for prosecution on the merits, along with any other of the pending claims that fall within the same group.

It is respectfully submitted that the elected group also includes method claims 38-52, which depend from claim 37 and incorporate its limitations. It is also submitted that claim 16 comes within the elected group, since it shares with claim 37 the object of using pPS cells in feeder-free culture, or the progeny of such cells, for the purpose of screening. Accordingly, claims 37-52 and 16 can be examined within the same group without imposing a burden on the Examiner (MPEP § 803).

PATENT
10/039,956
Docket 091/009c

The election is made without traverse. This is not meant to imply that applicant acquiesces to the propriety of the division of the claimed subject matter, or to the arguments made in support of the division in the Office Action.


Conclusion

Applicants respectfully request that the application proceed to examination on the merits, in view of the amendment and remarks made herein.

In the event the Examiner determines that an interview would facilitate prosecution of this application, she is invited to contact applicant's representative at the telephone number indicated below.

Should the Patent Office determine that an extension of time or any other relief is required for further consideration of this application, applicant hereby petitions for such relief, and authorizes the Commissioner to charge the cost of such petitions and other fees due in connection with the filing of these papers to Deposit Account No. 07-1139, referencing the docket number indicated above.

Respectfully submitted,



J. Michael Schiff
Registration No. 40,253

GERON CORPORATION
230 Constitution Drive
Menlo Park, CA 94025
Telephone: (650) 473-7715
Fax: (650) 473-8654

October 23, 2003

RECEIVED
CENTRAL FAX CENTER
OCT 23 2003

OFFICIAL

geron

**J. Michael Schiff
GERON CORPORATION
230 Constitution Drive
Menlo Park, CA 94025
Phone: (650) 473-7715
Fax: (650) 473-8654**

Last page of this transmission